Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 7:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 1,085 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Atherosclerosis Cardiovascular Disease Clear all
Completed Not applicable Interventional

High Fat Diet II on Weight Loss

NCT00525850
View directory record Official record
Conditions
Obesity
Interventions
high fat diet, low saturated fat diet
Other
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Aug 2, 2011 · Synced Oct 19, 2026, 7:18 AM EDT
Completed No phase listed Observational Results available

ION US Post-Approval Study

NCT01422889
View directory record Official record
Conditions
Atherosclerosis, Coronary Artery Disease
Interventions
ION™ Coronary Stent System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years to 110 Years
Enrollment
1,120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
40
States / cities
Jonesboro, Arkansas • Bakersfield, California • San Diego, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 19, 2026, 7:18 AM EDT
Completed Phase 3 Interventional

Evaluating Two Exercise Training Programs to Reduce Leg Pain in People With Peripheral Arterial Disease (The EXERT Study)

NCT00895635
View directory record Official record
Conditions
Intermittent Claudication, Peripheral Vascular Diseases
Interventions
Treadmill Exercise Training, Arm Ergometry Exercise Training, Usual Care
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 90 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 19, 2026, 7:18 AM EDT
Terminated Early Phase 1 Interventional

PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis

NCT03507374
View directory record Official record
Conditions
Stroke, Intracranial Atherosclerosis, Intraplaque Hemorrhage
Interventions
Alirocumab, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Oct 19, 2026, 7:18 AM EDT
Not listed Not applicable Interventional

The Young Heart Study

NCT04462159
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease, Coronary Artery Disease
Interventions
Risk Reduction Program
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 59 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 19, 2026, 7:18 AM EDT
Completed Phase 3 Interventional

A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia

NCT05610280
View directory record Official record
Conditions
Hypertriglyceridemia, Cardiovascular Diseases, Atherosclerosis
Interventions
Olezarsen, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
68
States / cities
Birmingham, Alabama • Huntsville, Alabama • Beverly Hills, California + 54 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 19, 2026, 7:18 AM EDT
Recruiting Not applicable Interventional

Fuzzy Wale Compression Stockinet to Promote Healing Following Transtibial Amputation for Peripheral Arterial Disease

NCT06308562
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Fuzzy Wale Compression Stockinet
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 19, 2026, 7:18 AM EDT
Completed Phase 1 Interventional

Combination Stem Cell (MESENDO) Therapy for Utilization and Rescue of Infarcted Myocardium

NCT00548613
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Arteriosclerosis, Coronary Atherosclerosis, Coronary Disease
Interventions
MESENDO
Biological
Lead sponsor
TCA Cellular Therapy
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Covington, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 28, 2011 · Synced Oct 19, 2026, 7:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of SB 659032 on Platelet Function

NCT01750827
View directory record Official record
Conditions
Atherosclerosis
Interventions
SB659032
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Oct 19, 2026, 7:18 AM EDT
Completed Not applicable Interventional Results available

Rotational Atherectomy Combined With Cutting Balloon to Optimize Stent Expansion in Calcified Lesions

NCT04865588
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis
Interventions
rotational atherectomy, cutting balloon, plain old balloon
Procedure · Device
Lead sponsor
Samin Sharma, M.D., F.A.C.C., M.S.C.A.I.
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
New York, New York • Roslyn, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 19, 2026, 7:18 AM EDT
Completed Phase 2 Interventional Results available

Dietary Nitrate and Exercise to Augment Exercise Training Benefits in Subjects With DM+PAD

NCT01785524
View directory record Official record
Conditions
Peripheral Arterial Disease, Type II Diabetes Mellitus
Interventions
Beetroot Juice (Beet-It Stamina Shot) and Exercise Training, Placebo Comparator Beverage (Beet-It Stamina Shot) & Exercise Training
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
50 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Oct 19, 2026, 7:18 AM EDT
Completed Early Phase 1 Interventional Results available

Ertugliflozin: Cardioprotective Effects on Epicardial Fat

NCT04167761
View directory record Official record
Conditions
Cardiovascular Diseases, Atherosclerosis, Type 2 Diabetes, Insulin Resistance
Interventions
Ertugliflozin
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 19, 2026, 7:18 AM EDT
Recruiting Not applicable Interventional

SCS for Patient With Painful Diabetic Neuropathy and Peripheral Arterial Disease

NCT06480786
View directory record Official record
Conditions
Peripheral Arterial Disease, Painful Diabetic Neuropathy, Diabetes Mellitus, Type 2, Chronic Pain, Spinal Cord Stimulation, Chronic Pain Syndrome, Limb Pain
Interventions
Spinal cord stimulation, Sham stimulation
Device
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 19, 2026, 7:18 AM EDT
Completed Not applicable Interventional

The Effect of Ischemic Conditioning on Strength and Ambulation in Subjects with PAD

NCT04937179
View directory record Official record
Conditions
Peripheral Arterial Disease, Peripheral Vascular Disease, Amputation, Lower Limb Amputation Knee, Lower Limb Amputation Above Knee (Injury), Lower Limb Amputation Below Knee (Injury)
Interventions
Ischemic Conditioning Low - Sham Comparator, Ischemic Conditioning High - Active Comparator
Procedure
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 19, 2026, 7:18 AM EDT
Not listed No phase listed Observational

Prediction of Progression of Coronary Artery Disease (CAD) Using Vascular Profiling of Shear Stress and Wall Morphology

NCT01316159
View directory record Official record
Conditions
Coronary Atherosclerosis, Acute Coronary Syndrome, Percutaneous Coronary Intervention, Endothelial Shear Stress, Arterial Remodeling
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2011 · Synced Oct 19, 2026, 7:18 AM EDT
Recruiting Not applicable Interventional

Leg Heat Therapy in Peripheral Artery Disease

NCT05465070
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Leg heat therapy, Sham Control
Device
Lead sponsor
Indiana University
Other
Eligibility
50 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 19, 2026, 7:18 AM EDT
Completed No phase listed Observational

Patterns of Inclisiran Use in the Real World: An Analysis of US Databases

NCT07023445
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
37,688 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Oct 19, 2026, 7:18 AM EDT
Terminated Not applicable Interventional Results available

Use of Clearway™ Balloon vs. Mechanical Thrombectomy as Initial Treatment for Acute Limb Ischemia

NCT00869375
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Endovascular peripheral intervention
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 19, 2026, 7:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

BE Study of Once Daily PMR Compared to Twice Daily Cilostazol Tablets in Healthy Volunteers

NCT06167265
View directory record Official record
Conditions
Intermittent Claudication
Interventions
Cilostazol Tablet 100 mg, PMR Tablet 145 mg
Drug
Lead sponsor
Genovate Biotechnology Co., Ltd.,
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 19, 2026, 7:18 AM EDT
Not listed Phase 4 Interventional

Effect of Evolocumab in Patients With Critical Limb Ischemia (Evol-CLI)

NCT04306471
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months., Placebo 1 milliliter (mL) Injector Pen x 3 monthly for 12 months
Drug · Other
Lead sponsor
Leonardo Clavijo
Other
Eligibility
40 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2020 · Synced Oct 19, 2026, 7:18 AM EDT
Completed Phase 2 Interventional Results available

A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease

NCT04992065
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
NNC0385-0434 A 15 mg, NNC0385-0434 A 40 mg, Placebo I A (for NNC0385-0434 A 15 mg), NNC0385-0434 A 100 mg, Placebo I A (for NNC0385-0434 A 40 mg), Placebo II A (for NNC0385-0434 A 100 mg), Evolocumab 140 mg/mL, Repatha®
Drug · Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
40 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
13
States / cities
Palm Springs, California • Boca Raton, Florida • Fort Lauderdale, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 19, 2026, 7:18 AM EDT
Terminated No phase listed Observational

Intravascular Ultrasound Derived Virtual Histology and Intracoronary Serum Markers of Inflammation

NCT00982852
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis, Myocardial Infarction, Heart Failure, Angina
Interventions
Not listed
Lead sponsor
Quinn Capers
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 12, 2013 · Synced Oct 19, 2026, 7:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Endothelial Function in Obese Adolescents

NCT01879033
View directory record Official record
Conditions
Insulin Resistance, Glucose Intolerance, Obesity, Atherosclerosis
Interventions
Reactive hyperemia peripheral artery tonometry (Rh-PAT), Blood levels for glucose, insulin, lipids and adipocytokines
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
12 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Oct 19, 2026, 7:18 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events

NCT07448038
View directory record Official record
Conditions
Atherosclerosis
Interventions
Selnoflast, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
24
States / cities
Beverly Hills, California • Irvine, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 19, 2026, 7:18 AM EDT